Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts - Role of A(2B) receptors

被引:119
作者
Dubey, RK [1 ]
Gillespie, DG [1 ]
Mi, ZC [1 ]
Jackson, EK [1 ]
机构
[1] UNIV PITTSBURGH,MED CTR,DEPT PHARMACOL,CTR CLIN PHARMACOL,PITTSBURGH,PA 15213
关键词
adenosine; myocardial infarction; hypertension;
D O I
10.1161/01.CIR.96.8.2656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Because proliferation of cardiac fibroblasts participates in cardiac hypertrophy/remodeling associated with hypertension and myocardial infarction, it is important to elucidate factors regulating cardiac fibroblast proliferation. Adenosine, a nucleoside abundantly produced by cardiac cells, is antimitogenic vis-g-vis vascular smooth muscle cells; however, the effect of adenosine on cardiac fibroblast proliferation is unknown. The objective of this study was to characterize the effects of exogenous and endogenous (cardiac fibroblast-derived) adenosine on cardiac fibroblast proliferation. Methods and Results Growth-arrested cardiac fibroblasts were stimulated with 2.5% FCS in the presence and absence of adenosine, 2-chloroadenosine (stable adenosine analogue), or modulators of adenosine levels, including (1) erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA; adenosine deaminase inhibitor); (2) dipyridamole (adenosine transport blocker); and (3) iodotubericidin (adenosine kinase inhibitor). All of these agents inhibited, in a concentration-dependent manner, FCS-induced cardiac fibroblast proliferation as assessed by DNA synthesis ([H-3]thymidine incorporation) and cell counting. EHNA, dipyridamole, and iodotubericidin increased extracellular levels of adenosine by 2.3- to 5.6-fold when added separately to cardiac fibroblasts, and EHNA+ iodotubericidin or EHNA + iodotubericidin + dipyridamole increased extracellular adenosine levels by >690-fold. Both KF17837 (selective A(2) antagonist) and DPSPX (nonselective A(2) antagonist) but not DPCPX (selective A(1) antagonist) blocked the antimitogenic effects of 2-chloroadenosine, EHNA, and dipyridamole on DNA synthesis, suggesting the involvement of A(2A) and/or A(2B) but excluding the participation of A(1) receptors. The lack of effect of CGS21680 (selective A(2A) agonist) excluded involvement of A(2A) receptors and suggested a major role for A(2B) receptors. This conclusion was confirmed by the rank order potencies of four adenosine analogues. Conclusions Cardiac fibroblasts synthesize adenosine,and exogenous and cardiac fibroblast-derived adenosine inhibits cardiac fibroblast proliferation via activation of A(2B) receptors. Cardiac fibroblast-derived adenosine may regulate cardiac hypertrophy and/or remodeling by modulating cardiac fibroblast proliferation.
引用
收藏
页码:2656 / 2666
页数:21
相关论文
共 31 条
  • [1] MOLECULAR SIGNALING MECHANISMS CONTROLLING GROWTH AND FUNCTION OF CARDIAC FIBROBLASTS
    BOOZ, GW
    BAKER, KM
    [J]. CARDIOVASCULAR RESEARCH, 1995, 30 (04) : 537 - 543
  • [2] BURNS RF, 1986, MOL PHARMACOL, V29, P331
  • [3] CORNSTEIN BN, 1986, J CLIN INVEST, V78, P760
  • [4] INHIBITION OF PLATELET-AGGREGATION BY ADENOSINE RECEPTOR AGONISTS
    CRISTALLI, G
    VITTORI, S
    THOMPSON, RD
    PADGETT, WL
    SHI, D
    DALY, JW
    OLSSON, RA
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1994, 349 (06) : 644 - 650
  • [5] DALZIEL HH, 1994, PHARMACOL REV, V46, P449
  • [6] CONTRIBUTION OF CORONARY ENDOTHELIAL-CELLS TO CARDIAC ADENOSINE PRODUCTION
    DEUSSEN, A
    MOSER, G
    SCHRADER, J
    [J]. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY, 1986, 406 (06): : 608 - 614
  • [7] Adenosine inhibits growth of rat aortic smooth muscle cells - Possible role of A(2b) receptor
    Dubey, RK
    Gillespie, DG
    Osaka, K
    Suzuki, F
    Jackson, EK
    [J]. HYPERTENSION, 1996, 27 (03) : 786 - 793
  • [8] Dubey RK, 1996, HYPERTENSION, V28, pP7
  • [9] Cyclic AMP Adenosine pathway inhibits vascular smooth muscle cell growth
    Dubey, RK
    Mi, ZC
    Gillespie, DG
    Jackson, EK
    [J]. HYPERTENSION, 1996, 28 (05) : 765 - 771
  • [10] EGHBALI M, 1992, BASIC RES CARDIOL, V87, P183